Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Adial Pharmaceuticals has extended its CEO Cary Claiborne’s tenure with a new three-year employment agreement effective from December 5, 2024. The revised terms include a higher bonus target, set at 50% of Claiborne’s base salary contingent on meeting specific objectives, and stock options for 350,000 shares under the company’s equity plan, vesting over 36 months.
See more insights into ADIL stock on TipRanks’ Stock Analysis page.